Sitemap - 2023 - Big Pharma Sharma
Five Lists of Five: An End of 2023 Recap
ASH 2023 Zeitgeist Review: Winners and Losers
Big Pharma Sharma's Bullets: Implications from a Few Major News Items this Week
Everybody is in Cell Therapy Now
Cell Therapy for Type 1 Diabetes Landscape
Diving into the Clinical Immune Cell Therapy Landscape for Autoimmune Diseases
ASH 2023 non-LBA Most Interesting Abstracts
My Three Big Winners from ESMO
ESMO 2023: BioNTech’s Cell Therapy Programs Leave Me with More Questions than Answers.
ANALYZING BMS’ ACQUISITION OF MIRATI
ESMO 2023: Most Interesting Late Breaking Abstracts
Double-Clicking into BioPharma IPOs
ESMO 2023: My Most Interesting Abstracts
Big Pharma Sharma's Bullets: Imbruvica’s Decline, IRA Crosshairs, and What it Could Mean for AbbVie
BBT: Replimune (REPL) Looking to Restore the Promise of Oncolytic Viruses in Skin Cancer and Beyond
BioPharma Buyout Targets (BBT): ImmunoGen (IMGN) Presents an Interesting Path to ADC Leadership
Big Pharma (L)Earnings Q2’23 | Gilead, Regeneron, Amgen, Moderna, Bayer, Lilly
Big Pharma (L)Earnings Q2'23 | BMS, AbbVie, Sanofi, AstraZeneca, Merck, Pfizer, Vertex
Big Pharma (L)Earnings Season Q2'23: J&J, Novartis, Biogen, Roche
The Limited Speed of Fast CARs
Priority Review Voucher (PRV) Database: Trends, Analysis, Insights, and Future Strategies
Amazon Should Buy a Generic Drug Manufacturer
ASCO/EHA/ICML 2023 Look-back: CAR-T Remains King in DLBCL and MM